378 related articles for article (PubMed ID: 19150547)
41. Testosterone and prostate cancer: what are the risks for middle-aged men?
Morgentaler A
Urol Clin North Am; 2011 May; 38(2):119-24. PubMed ID: 21621078
[TBL] [Abstract][Full Text] [Related]
42. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.
Pisters LL; Leibovici D; Blute M; Zincke H; Sebo TJ; Slezak JM; Izawa J; Ward JF; Scott SM; Madsen L; Spiess PE; Leibovich BC
J Urol; 2009 Aug; 182(2):517-25; discussion 525-7. PubMed ID: 19524984
[TBL] [Abstract][Full Text] [Related]
43. Metabolic and cardiovascular effects of androgen deprivation therapy.
Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
[TBL] [Abstract][Full Text] [Related]
44. Diet and dietary supplement intervention trials for the prevention of prostate cancer recurrence: a review of the randomized controlled trial evidence.
Van Patten CL; de Boer JG; Tomlinson Guns ES
J Urol; 2008 Dec; 180(6):2314-21; discussion 2721-2. PubMed ID: 18930254
[TBL] [Abstract][Full Text] [Related]
45. [Time-course of plasma testosterone in patients with prostate cancer treated by endocrine therapy].
Peyromaure M; Rebillard X; Ruffion A; Salomon L; Villers A; Soulie M;
Prog Urol; 2008 Jan; 18(1):2-8. PubMed ID: 18342148
[TBL] [Abstract][Full Text] [Related]
46. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
Park YH; Hwang IS; Jeong CW; Kim HH; Lee SE; Kwak C
J Urol; 2009 Jun; 181(6):2520-4; discussion 2525. PubMed ID: 19371894
[TBL] [Abstract][Full Text] [Related]
47. Testosterone loss and estradiol administration modify memory in men.
Beer TM; Bland LB; Bussiere JR; Neiss MB; Wersinger EM; Garzotto M; Ryan CW; Janowsky JS
J Urol; 2006 Jan; 175(1):130-5. PubMed ID: 16406889
[TBL] [Abstract][Full Text] [Related]
48. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
49. Prostogram predicted brachytherapy outcomes are not universally accurate: an analysis based on the M. D. Anderson Cancer Center experience with (125)iodine brachytherapy.
Frank SJ; Levy LB; Kuban DA; Lee AK; Kudchadker RJ; Bruno TL; van Vulpen M; Swanson DA
J Urol; 2009 Apr; 181(4):1658-63; discussion 1663-4. PubMed ID: 19233434
[TBL] [Abstract][Full Text] [Related]
50. Testosterone replacement therapy and prostate risks: where's the beef?
Morgentaler A
Can J Urol; 2006 Feb; 13 Suppl 1():40-3. PubMed ID: 16526980
[TBL] [Abstract][Full Text] [Related]
51. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer.
Gleave M; Klotz L; Taneja SS
Urol Oncol; 2009; 27(1):81-6. PubMed ID: 19111804
[TBL] [Abstract][Full Text] [Related]
52. The dark side of testosterone deficiency: III. Cardiovascular disease.
Traish AM; Saad F; Feeley RJ; Guay A
J Androl; 2009; 30(5):477-94. PubMed ID: 19342698
[TBL] [Abstract][Full Text] [Related]
53. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C
Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426
[TBL] [Abstract][Full Text] [Related]
54. Testosterone and the aging male.
Tenover JL
J Androl; 1997; 18(2):103-6. PubMed ID: 9154502
[TBL] [Abstract][Full Text] [Related]
55. Androgen therapy for loss of desire in women: is the benefit worth the breast cancer risk?
Schover LR
Fertil Steril; 2008 Jul; 90(1):129-40. PubMed ID: 18023435
[TBL] [Abstract][Full Text] [Related]
56. Testosterone replacement therapy and the risk of prostate cancer. Is there a link?
Barqawi A; Crawford ED
Int J Impot Res; 2006; 18(4):323-8. PubMed ID: 16281043
[TBL] [Abstract][Full Text] [Related]
57. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
Sun L; Caire AA; Robertson CN; George DJ; Polascik TJ; Maloney KE; Walther PJ; Stackhouse DA; Lack BD; Albala DM; Moul JW
J Urol; 2009 Nov; 182(5):2242-8. PubMed ID: 19758616
[TBL] [Abstract][Full Text] [Related]
58. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
Bañez LL; Sun L; Trock BJ; Han M; Partin AW; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Moul JW; Freedland SJ
J Urol; 2009 Aug; 182(2):491-6; discussion 496-8. PubMed ID: 19524974
[TBL] [Abstract][Full Text] [Related]
59. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
[TBL] [Abstract][Full Text] [Related]
60. Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores.
Liauw SL; Fricano J; Correa D; Weichselbaum RR; Jani AB
Cancer; 2009 Apr; 115(8):1784-90. PubMed ID: 19208426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
